Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients-Reference-Cited by-同舟云学术

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients

Published:2010-11 Issue:11 Volume:34 Page:1430-1436
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Park Sophie,Kelaidi Charikleia,Sapena Rosa,Vassilieff Dominique,Beyne-Rauzy Odile,Coiteux Valérie,Vey Norbert,Ravoet Christophe,Cheze Stéphane,Rose Christian,Legros Laurence,Stamatoullas Aspasia,Escoffre-Barbe Martine,Guerci Agnès,Chaury Marie-Pierre,Fenaux Pierre,Dreyfus François

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes;Jabbour;Cancer,2008

2. Impact of anemia on hospitalization and mortality in older adults;Culleton;Blood,2006

3. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report;Clavio;Eur J Haematol,2004

4. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making;Malcovati;J Clin Oncol,2005

5. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life;Hellstrom-Lindberg;Br J Haematol,2003

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2024-05-04

2. Transfusion avoidance in myelodysplastic neoplasms;Current Opinion in Hematology;2023-11-16

3. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data;Turkish Journal of Hematology;2023-05-30

4. Myelodysplastic syndromes with ring sideroblasts;Hematological Oncology;2023-02-26

5. Myelodysplastic Syndromes;Holland‐Frei Cancer Medicine;2022-10-21